Thank you very much for submitting your research paper for consideration to The EMBO Journal editorial office. Three expert referees initially agreed to assess merits and suitability of your paper for our journal. I did receive comments of two scientists that enable reaching a decision and at the same time prevent further unnecessary delay for you and your study. As you will see, ref#1 raises very strong conceptual concerns as the notion that Gaba-B receptors form higher order oligomers had already been conveyed in one of your earlier studies. Consistent with this, this scientist would only be willing to offer support for further consideration here if significant further support of the nature and kind of such oligomers at the endogenous level could be provided (point2, ref#1). Further, the recent competitor strategy seems not as conclusive as presented in the paper and demands further detailed mapping before providing compelling evidence for the proposed model (point1, ref#1). Only if these points are thoroughly answered (together with the mostly technical concerns from ref#2), the study might present the significant advance and definitive insight that we have to demand according to the aim and scope of our journal. We are certainly aware that this amounts to a lot of further experimentation, resources and efforts and seems very unlikely to be achieved during the strictly limited round of single major revision. Please understand that with this clear assessment reflecting the very premature stage of the current study, we are unable to commit to your manuscript at this point. Based on this judgment, I do have no other choice than to formerly reject the paper.
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Thank you very much for submitting your research paper for consideration to The EMBO Journal editorial office. Three expert referees initially agreed to assess merits and suitability of your paper for our journal. I did receive comments of two scientists that enable reaching a decision and at the same time prevent further unnecessary delay for you and your study. As you will see, ref#1 raises very strong conceptual concerns as the notion that Gaba-B receptors form higher order oligomers had already been conveyed in one of your earlier studies. Consistent with this, this scientist would only be willing to offer support for further consideration here if significant further support of the nature and kind of such oligomers at the endogenous level could be provided (point2, ref#1). Further, the recent competitor strategy seems not as conclusive as presented in the paper and demands further detailed mapping before providing compelling evidence for the proposed model (point1, ref#1). Only if these points are thoroughly answered (together with the mostly technical concerns from ref#2), the study might present the significant advance and definitive insight that we have to demand according to the aim and scope of our journal. We are certainly aware that this amounts to a lot of further experimentation, resources and efforts and seems very unlikely to be achieved during the strictly limited round of single major revision. Please understand that with this clear assessment reflecting the very premature stage of the current study, we are unable to commit to your manuscript at this point. Based on this judgment, I do have no other choice than to formerly reject the paper.
Still appreciating the inherent potential of your data, but certainly conditioned on your ability and willingness to take it significantly further, we might re-consider a new version at least at the editorial level in the future.
I do have to emphasize that this would not be treated as a simple revision, but has to be assessed as NEW SUBMISSION. It would therefore be evaluated afresh, also with respect to the literature and the novelty of your findings at the time of submission. Further, I do have to stress that our experience with this type of submissions is overall not a very positive one, as authors tend to underestimate the actual need for significant further experimentation. We would thus understand if you would rather decide to seek more rapid publication elsewhere.
I am really sorry that we are unable to reach a more positive conclusion. I still hope that communicating clearly our demands and expectations together with the comments of our referees might guide your decision on how to proceed with the current work.
Yours sincerely,
Editor
The EMBO Journal REFEREE REPORTS:
Referee #1 (Remarks to the Author):
This manuscript describes studies aimed at assessing receptor-receptor interactions between GABA-B receptors in both transfected cells and native brain tissue. The authors' conclusions are that GABA-B receptors assemble into higher-order complexes (at least tetramers) via interactions between their GB1 subunits, and that disruption of these higher-order complexes results in enhanced functional activity of GABA-B receptors. These conclusions are identical to the conclusions reached in a previous publication from the same group (Maurel et al., Nature Methods, 2008) . The current manuscript describes new technical approaches that serve to confirm the conclusions of the earlier paper while also extending these conclusions to GABA-B receptors in native brain tissue (the earlier paper focused only on transfected cells). Thus, while the current manuscript describes some interesting technical advances, the conceptual advances over earlier work are rather incremental in nature. Specific comments are as follows:
1. One of the technical advances in the current manuscript is the use of a different "competitor" construct to bind GB1 and block GB1-GB1 interactions: the construct used here is a version of GB1 lacking its ligand binding site and C-terminus ("GB1deltaBdeltaCT"), whereas in the previous paper the competitor was the seven-transmembrane domain of GB1. However, both of these competitor constructs represent imperfect tools, since in addition to blocking GB1-GB1 interactions they will also create new receptor complexes with potentially complicated properties. For example, in the studies described in the current manuscript, transfection of GB1deltaBdeltaCT into cells also transfected with GB1 & GB2 will presumably result in the creation of GB1/GB2/GB1deltaBdeltaCT complexes, which might inherently have enhanced functional activity relative to GB1/GB2 alone. To put it another way, transfection of the GB1deltaBdeltaCT mutant might potentiate GABA-B signaling not because it disrupts the formation of tetramers (or higher-order oligomers) but rather because it creates an unnatural complex with GB1/GB2 that happens to have enhanced signaling activity. A better approach would be to map the structural determinants on the GB1 N-terminus that control GB1-GB1 interactions and then create a mutant GB1 that is incapable of associating with other GB1 subunits. If transfection of this mutant version of GB1 with GB2 resulted in greatly enhanced GABA-B receptor signaling relative to wild-type GB1/GB2, this would represent more compelling evidence for the authors' model than the studies using the competitor constructs.
2. The authors repeatedly refer to the higher-order GABA-B receptor complexes as "tetramers", but no evidence is provided that these complexes are actually tetramers and not higher-order complexes (hexamers, octamers, etc.) . It would add significant novelty to the current study if the authors could provide evidence that GABA-B receptors do indeed form tetramers. One approach that might help to establish this would be a purification and reconstitution approach similar to that described by Fung et al. (EMBO J. 28:3315-3328, 2009 ).
3. Many of the data sets shown in the various figures of this manuscript require statistical analyses to establish the significance of key comparisons between data sets.
Referee #2 (Remarks to the Author):
1. In Figure 1 , the control with Flag-GB1 and HA-GB1 but no GB2 should be shown, to validate the statement in the text that cell surface GB1-GB1 co-precipitation requires GB2.
2. In Figure 1D (and in other figures throughout), the FRET signal is shown in units c.p.s., which is undefined. The corrections applied to derive the final specific FRET values are fairly complex, and involve the differences between relatively large, experimentally determined (and therefore potentially variable) values. It would therefore be reassuring to present more explicit statistical tests for these assays, instead of simply mean {plus minus} SEM.
3. In Figure 2B , the specific anti-sushi antibody binding to brain membranes measured by donor emission gives a very small signal compared to the non-specific binding, even using GB1 knockout samples. Can specificity for antibody binding to GB1 in membranes also be shown by a distinct method, such as by pre-incubating the labeled sushi antibodies with antigen (peptide or recombinant sushi domain)? In Figure 2C , do GB1 knockout mouse synaptosome membranes also lack FRET signal? Can this technique be used to demonstrate receptor tetramer FRET in a truly minimallymanipulated system, such as a brain slice or cultured primary neurons in vitro? Minor issue: in Figure 2A , the axis should be labeled "GB1 cell surface expression" (not "GB1a"), since both GB1a and GB1b forms are tested. Figures 3 and S3 utilize GB1/2 and GB2/1 chimeras. Do these constructs have intact carboxyl termini to allow normal dimerization, and if so, does GB1/2 have the 2 CT and GB2/1 have the 1 CT, or do both have GB1 CT? In order to conclude that GB1-VFT alone mediates ST-ST FRET (and thus tetramerization), both chimeras should have the same CT region (GB1). Figure 4 presume that GB1-deltaB-deltaCT + GB2 is totally inactive as a GABA receptor, but this combination is never tested directly.
Experiments in

The G protein coupling tests in
6. The conclusion from Figure 6 is that the data "tend to suggest that a single G-protein can be activated by the GABA-B tetramer." This should be clarified, to something like "G proteins are more efficiently activated by an active half-tetramer, suggesting that only a single G protein may be able to bind productively to the tetramer."
Additional Author Correspondence 22 July 2010
Many thanks for your message. Regarding the major criticisms of the first referee, we already have the data tin hands to answer these two points:
1) we have precisely mapped the interacting interface between the GB1 subunits responsible for the tetramerization, and generated a single point mutant that no longer forms tetramers in transfected cells as revealed by cell surface FRET data. This mutant receptor is well targeted to the cell surface, binds GABA and other GABAB ligands with the same affinity, and most importantly, this receptor display a higher G-protein coupling efficacy, as measured at the same receptor density at the cell surface. This nicely responds to the first major point of the ref #1
2) regarding the second point: we think that the experiments with the mutant GABAB1 subunit describes above further validate that the GABAB oligomer is limited to tetramers. Indeed if higher ordered oligomers would exist, such oligomers would imply that the GABAB1 subunit has at least three interacting interfaces: one to associate with GABAB2 (this interface has been already identified in Rondard et al., EMBOJ 2008), a second one responsible for the association between two heterodimers, to form a tetrameric unit, and, because GB2 subunits are never in close enough proximity, the GB1 subunit should have a third interface responsible for the formation of higher ordered oligomers. Our observation that a single point mutation suppressed GB1-GB1 interaction, reresent a convincing evidence that there are only two interaction interfaces, then limiting the receptor complex to just a dimer of heterodimers.
Regarding the experiment suggested by the referee, the approach proposed is subjected to strong criticisms by biophysicists, and would not apply to the GABAB receptor. Indeed, the approach implies that the four subunits in the tetramer should be perfectly interchangeable and FRET should be equaly efficacious between each subunits, and this is clearly not the case for the GABAB receptor since no FRET can be measured between GABAB2 subunits within the tetramer.
Accordingly, we are ready to submit a revised version of our manuscript within the next two months, and would greatly appreciate if you could reconsider your decision, and accept that we simply submit a revised version, rather that preparing a new submission.
Additional Editorial Correspondence 22 July 2010
I am happy to hear that you might have the essential further support for your interesting proposal already at hand. However, there is no actual need to change the current decision status, as the paper would end on my desk anyway and I will look at it carefully. If it addresses all points, I will run it with the critical referee. If I am still in doubt I might involve another, so far unbiased scientist.
The final decision will be made based on the content of a new version in any case. The current status enables you to take more time than the strict limit of a normal revision.
I wish you all the best for future experimentation and will be happy to receive a modified version of your paper in the future. In our previous study by Maurel et al (2008), we concentrated on the development of a new method to study receptor oligomers. This method was instrumental in demonstrating for the first time that, in contrast to the mGlu receptors, the GABAB receptor heterodimers can spontaneously assemble into larger complexes through interaction of the GB1 subunits. Although disruption of the GABAB oligomers using the GB1 7TM was achieved and described in Maurel et al (2008) , and shown to result in an increased G protein mediated response, the main reason for this effect was far from being clear.
Accordingly, our present manuscript reports major new findings in this area:
1-Most importantly we provide evidence that such GABAB "tetramers" (or larger complexes) are not an artifact of the over-expression in transfected cells, since i) they can be observed at an expression level similar to that of cultured neurons, and ii) they can be detected in the brain using fluorescently labeled antibodies.
2-We show that the GABAB1 VFT plays a critical role in such GABAB receptor assembly 3-We confirmed that dissociation of the tetramer using a competing subunit increases GABAB receptor G protein coupling efficacy 4-We showed for the first time that the native Gi coupling was also sensitive to the oligomerization 5-Based on analogy with the AMPA receptor dimer of dimers, we now identify a contact zone within the GB1 VFT that is responsible for the formation of GABAB oligomers. 6-We confirmed this proposal as we obtained a GABAB mutant that destabilizes tetramer formation. Such mutant confirmed the lower coupling efficacy of a GABAB tetramer, versus dimers. 7-We provide evidence that in a GABAB tetramer, activation of a single dimer is sufficient for maximal G protein activation. 8-Accordingly, our data illustrate a clear negative allosterism between the GABAB heterodimers when associated in tetramers. We think these data represent major new information.
Specific comments are as follows:
One of the technical advances in the current manuscript is the use of a different "competitor" construct to bind GB1 and block GB1-GB1 interactions: the construct used here is a version of GB1 lacking its ligand binding site and C-terminus ("GB1deltaBdeltaCT"), whereas in the previous paper the competitor was the seven-transmembrane domain of GBHowever, both of these competitor constructs represent imperfect tools, since in addition to blocking GB1-GB1 interactions they will also create new receptor complexes with potentially complicated properties. For example, in the studies described in the current manuscript, transfection of GB1deltaBdeltaCT into cells also transfected with GB1 & GB2 will presumably result in the creation of GB1/GB2/GB1deltaBdeltaCT complexes, which might inherently have enhanced functional activity relative to GB1/GB2 alone. To put it another way, transfection of the GB1deltaBdeltaCT mutant might potentiate GABA-B signaling not because it disrupts the formation of tetramers (or higher-order oligomers) but rather because it creates an unnatural complex with GB1/GB2 that happens to have enhanced signaling activity. A better approach would be to map the structural determinants on the GB1 N-terminus that control GB1-GB1 interactions and then create a mutant GB1 that is incapable of associating with other GB1 subunits. If transfection of this mutant version of GB1 with GB2 resulted in greatly enhanced GABA-B receptor signaling relative to wild-type GB1/GB2, this would represent more compelling evidence for the authors' model than the studies using the competitor constructs.
The referee is right, our competition analysis was not perfectly conclusive since the activity measured never really corresponded to that of dimers, but rather to dimers associated with the competing subunit (as illustrated in Fig 4A) .
The referee suggested that we look for the structural determinants on the GB1-VFT that control GB1-GB1 interaction. We have now generated data in that prospect. As illustrated in the new Fig 5, we now report the identification of a contact area between the GABAB dimers at the level of the GB1 VFT. Of note, any attempt to prevent GABAB tetramer assembly through a glycan-wedge strategy was not succesful when the glycosylation sites were introduced at the opposite side of the GB1-GB2 interface (Supp Fig S7) . We then analyzed whether the dimer of dimers could be assembled as recently reported in the AMPA receptor structure. In agreement with this possibility, we identified a mutation at this level that was sufficient to largely decrease the FRET signal between the GB1 subunits, demonstrating that the GABAB tetramer was destabilized by this mutation.
Of interest, and consistent with the competition approach, the G protein coupling efficacy of such GABAB mutant was enhanced, as illustrated by the larger response observed, supporting once again that the disturbance of the GB1-GB1 interaction affects the G protein signaling. Fung et al. (EMBO J. 28:3315-3328, 2009 ).
The authors repeatedly refer to the higher-order GABA-B receptor complexes as "tetramers", but no evidence is provided that these complexes are actually tetramers and not higher-order complexes (hexamers, octamers, etc.). It would add significant novelty to the current study if the authors could provide evidence that GABA-B receptors do indeed form tetramers. One approach that might help to establish this would be a purification and reconstitution approach similar to that described by
As indicated in the introduction of our manuscript, the term "tetramer" was used by simplicity, exactly like many authors used the term "dimers" and clearly mention that these might be higher ordered oligomers. We are well aware of the limits of such simplified presentation.
The referee suggested that we used purified and reconstituted receptors to clarify this issue. So far no one has succeeded in purifying and reconstituting any full length class C GPCRs. We have been working hard on this issue with mGlu receptors and only succeeded in obtaining the 7TM portion of these receptors purified and reconstituted. Although the referee's suggestion would certainly brings information along these lines, we preferred to examine the stoichiometry using an approach in cultured cells, as we used recently (Doumazane, Scholler et al., FASEB J 2011). However, we did not succeeded in getting conclusive data likely because the subunit organization is not homogenous, since almost no FRET can be measured between GABAB2 subunits. Although we could not bring a clear conclusion regarding the exact stoichiometry, we think our data are still best explained by GABAB tetramers, as now discussed in our manuscript. i) In addition to the strict tetramers, only a specific organization into hexamers or octamers (supp Fig S1) , are consistent with our TR-FRET data (the referee should not forget that the TR-FRET efficacy is only dependent on the distance between the fluorophores, and is not influenced by a possible orientation constraint (see Bazin et al. 2002 and Selvin et al. 2002)) . ii) Only the tetramer allows a symmetrical assembly of the GB1 VFTs, the other possibilities imply that the interface identified interacts with a different area in the associated GB1 VFT (unlikely because of the absence of dissociation observed with many glycosylation mutants (Supp Fig. S7) ).
iii) The tetramer model fits with the structure of the AMPA receptor. iv) Bettler and co-workers identified GABAB tetramers associated with the KCTD proteins, and did not find evidence for higher complexes (Shwenk et al, 2010) 
Many of the data sets shown in the various figures of this manuscript require statistical analyses to establish the significance of key comparisons between data sets.
Statistical analyses have been performed and added in the figures. Sorry for the omission of these in our previous version of the manuscript.
Referee #2:
The sentence in the previous version of the ms "cell surface Flag-GB1 could coimmunoprecipitate HA-GB1 in the presence of GB2" was a syntax error as we meant that GB1 could immunoprecipitate another GB1 from the cell surface when transfected with GB2 and NOT that GB2 was a requirement for the immunoprecipitation to occur. Indeed, to perform these experiments, the anti-tag antibody was incubated with intact cells, allowing the labeling of cell surface receptors exclusively. GB1 does not reach the cell surface in the absence of GB2, such that the proposed control would not bring much information. Accordingly, our sentence was modified to state " Flag-GB1 was found to efficiently co-immunoprecipitate HA-GB1 while Flag-mGlu5 failed (GB2 being co-expressed in all conditions), demonstrating the specificity and the stability of the GB1-GB1 interaction in transiently transfected COS7 cells " Note that in the absence of GB2, GB1 does not reach the cell surface, then cannot be labeled on intact cells, and then will not be immunoprecipitated under these conditions. Figure 1D ( Despite the high non specific binding observed with the anti-sushi antibodies, we do believe that the significance of the signal is good. Indeed, the non-specific binding recorded from wild-type mice is very similar to that measured from mice lacking the epitope (GB1-/-). This supports that any signal above this value is specific and arises from the presence of GB1a in the sample. The high unspecific labeling could arise from several parameters like adsorption of the antibody on the membranes or the tube, remaining of unbound antibody despite extensive washing… It could be interesting to test whether GB1-/-mouse synaptosomes also lack FRET signal. However, we have shown already that no FRET signal could be detected on brain membranes from the GB1-/-animal and no specific binding of the antibody could be detected making us believe that no FRET signal could be detected even on fractions enriched in synaptosomes from these animals. Also, technical difficulties of mouse handling between France and Switzerland made us performing the experiment on knock-out animals using frozen brains, thus incompatible with the preparation of synaptosomes.
In
We have tried to use a similar technique in a "trully minimally-manipulated system", i.e. primiray culture of cortical neurons. However we failed because we have not been able to detect significant binding of the anti-sushi antibodies, indicating that only a small fraction of the receptors are labeled, making such labeling incompatible with FRET studies. Indeed, while the anti-sushi antibody (unlabeled) has been used previously to label GABAB receptor in cultured neurons in immunofluorescence experiments, the signal appeared to be rather low (Bettler et coll. Personal communication) . This could be due to the formation of the extracellular matrix that is well described to interact with several proteic motives such as sushi domains. Hence, it is most likely that the epitope of the antibody is masked by the extracellular matrix and thus only binds to a small fraction of the receptors. When preparing brain membrane or synaptosomes, the experimental procedure allows most probably to get rid of the extracellular matrix and thus the antibody can bind to most of GB1a present in the sample. Figure 2A , the axis should be labeled "GB1 cell surface expression" (not "GB1a"), since both GB1a and GB1b forms are tested. The chimeras were constructed such that only the VFTs have been swapped. Consequently, GB1/2 and GB2/1 possess the C-term tail of GB2 and GB1, respectively. We mention the importance of the VFT to mediate the tetramerization, however, we do not affirm that the VFT-alone is responsible for this organization. In addition, with the new data obtained with the mutant (Fig 5) , we provide further indication that disturbing the VFT does result in a FRET decrease. Figure 4 presume that GB1-deltaB-deltaCT + GB2 is totally inactive as a GABA receptor, but this combination is never tested directly.
Minor issue: in
The G protein coupling tests in
The combination GB1-B-CT + GB2 was tested in a Ca2+ assay and was not activated by GABA (see figure below) . Note that the two mutations in the GABA binding site (S246A and E465A) were described previously and were shown to largely decrease GABA binding and G protein coupling efficiency (Galvez et al 1999 , Kniazeff et al. 2002 .
In addition, in the experiment illustrated in Figure 4 , we used Myc-GB2-KKXX that carries a retention signal in its C-terminal tail and can reach the cell surface only in the presence of a GB1 full-length. As a consequence, a GB1 deprived of its Cterminal tail cannot mask the KKXX motif and does not interact directly with GB2.
The conclusion from Figure 6 is that the data "tend to suggest that a single G-protein can be activated by the GABA-B tetramer." This should be clarified, to something like "G proteins are more efficiently activated by an active half-tetramer, suggesting that only a single G protein may be able to bind productively to the tetramer."
The sentence has been changed to "The extent of G protein activation when a single GB2 in the tetramer can couple suggests that only a single G protein can be activated by the GABAB tetramer." Your re-submitted manuscript has now been re-assessed by two original referees. One of them suggests minor text changes that I kindly ask you to consider before ultimate acceptance of your paper.
On this occasion, please also include an 'author contribution statement' after the acknowledgement section that specifies the contribution of every listed author and their understanding of the responsibilities connected to authorship.
Looking forward to your response.
Editor
